Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Church & Dwight Co., Inc. (CHD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Church & Dwight Co., Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Church & Dwight Co., Inc. trades at $97.48 (market cap $22.83B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Church & Dwight Co., Inc. pays a 1.28% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | CHD | |
|---|---|---|
Market Cap | $39.89B | $22.83B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $105.26 |
52-Week Low | $278.09 | $81.60 |
Enterprise Value | $38.15B | $24.53B |
Dividend Yield | — | 1.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Church & Dwight (CHD) trades at $96.36, up 0.72% today, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 adjusted EPS of $0.95, exceeding expectations, driven by 5% organic sales growth. Recent acquisition of Miss Mouth's brand for $325 million aims to strengthen its fabric care portfolio. Cash flow trends show a net outflow in 2025, though operating cash flow remains robust at $1.22 billion.
Outlook remains positive with a consensus price target of $101.33, implying 5% upside, supported by strong analyst sentiment (53% buy ratings). Risks include margin pressure from inflation and competitive threats in consumer staples. The stock's valuation at 31.7x P/E requires sustained earnings growth to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Church & Dwight Co., Inc.
Church & Dwight is the leading producer of baking soda in the world. Beyond baking soda, the products in its portfolio have vast category reach, including laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its mix also includes Xtra, Trojan, OxiClean, First Response, Nair, L'il Critters/Vitafusion, Orajel, and WaterPik, which together with Arm & Hammer constitute more than 80% of its annual sales and profits. In early 2019, the firm announced the addition of Flawless, which manufactures electric shaving products for women. At the end of 2020, the firm acquired Zicam, a leading brand in the cough/cold-shortening category. Church & Dwight derives more than 80% of its sales from its home market in the U.S.
Read more on CHD →
